DCF Advisers LLC raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,804 shares of the medical equipment provider's stock after acquiring an additional 3,985 shares during the quarter. Zimmer Biomet makes up 1.5% of DCF Advisers LLC's portfolio, making the stock its 22nd biggest holding. DCF Advisers LLC's holdings in Zimmer Biomet were worth $3,034,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Garde Capital Inc. purchased a new stake in shares of Zimmer Biomet in the first quarter worth about $29,000. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $30,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the 1st quarter valued at $30,000. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the 1st quarter valued at $30,000. Finally, Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 88.89% of the company's stock.
Insider Buying and Selling
In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.70% of the stock is owned by company insiders.
Zimmer Biomet Price Performance
Shares of ZBH traded down $1.29 during mid-day trading on Wednesday, reaching $90.76. The stock had a trading volume of 291,039 shares, compared to its average volume of 2,068,108. The firm has a market cap of $17.96 billion, a price-to-earnings ratio of 20.10, a PEG ratio of 2.16 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $116.71. The business has a fifty day moving average of $93.12 and a 200 day moving average of $100.01. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.94 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.
Zimmer Biomet Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were paid a $0.24 dividend. The ex-dividend date was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.
Wall Street Analyst Weigh In
ZBH has been the subject of a number of research analyst reports. Evercore ISI reduced their target price on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company lowered their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Raymond James Financial cut their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average price target of $111.39.
Check Out Our Latest Stock Analysis on ZBH
Zimmer Biomet Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Recommended Stories

Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.